Market Snapshot – Friday, 23 March 2026
At 10:02 PM Central Europe, shares of Tianjin Pharmaceutical Da (T14.SI) slipped 2.62 % from the previous close. The Singapore-listed stock currently trades at roughly USD 2.56 on major exchanges. With an outstanding supply of 200 million shares, the company’s market capitalisation stands at USD 4.1 billion. In the last 24 hours, approximately USD 212.7 k worth of shares changed hands.
The firm has moved +1.96 % since the end of February. Its 200‑day simple moving average is USD 3.00, while the 52‑week high of USD 3.75 was recorded on 23 February 2026. The lowest point in the same period—USD 2.45—occurred on 11 September 2026.
Contextualising the Move
Tianjin Pharmaceutical Da’s recent dip reflects broader volatility in the pharmaceutical sector, particularly in China’s domestic market. The company, established in 1992 and headquartered in Tianjin, operates across a spectrum that includes traditional Chinese medicine, western pharmaceuticals, biological products, and healthcare services. Its strategic partnership with Ping An Good Doctor and diversified product portfolio have historically anchored investor confidence.
In the past 24 hours, the stock’s performance sits comfortably within the trend exhibited by a handful of peers:
| Stock | 24‑Hour Change | Current Price | Market Cap | P/E |
|---|---|---|---|---|
| Novoray (688300.SS) | 0 % | CNY 94.31 | CNY 32.1 bn | 104.44 |
| JD (9618.HK) | –4.28 % | HKD 100 | HKD 37.1 bn | 17.05 |
| Beijing Tongrentang (600085.SS) | 0 % | CNH 24.64 | CNH 34.1 bn | 35.13 |
| Chongqing Afari (601777.SS) | 0 % | CNH 7.92 | CNH 35 bn | 245.25 |
| Quectel Wireless (603236.SS) | 0 % | CNH 80.74 | CNH 34 bn | 25.51 |
Peer‑Group Highlights
JD faced a sharp sell‑off following regulatory scrutiny over product‑quality and safety reviews. The company’s shares fell between 4 % and 6 % after Chinese regulators called several e‑commerce firms, including JD and Alibaba, for reviews. This regulatory focus, coupled with concerns over the profitability of AI and semiconductor investments, added to a broader technology‑stock sell‑off on Hong Kong and Shanghai exchanges.
Beijing Tongrentang announced a strategic acquisition of a competing pharmaceutical distributor, leading to an overlap between its retail and wholesale operations. The controlling shareholder pledged a five‑year commitment to address competitive issues, though specific timelines remain unclear. Recent financial results show a downturn in both industrial and commercial segments, and the company’s retail network has contracted.
Chongqing Afari has accelerated the commercialization of its autonomous driving technology, extending its ASD 4.0 system across a wider range of vehicle models. The company’s investment in R&D, particularly in L2–L4 technology and AI partnerships, positions it to capture growing demand for accessible advanced driver assistance in China’s automotive market.
Quectel Wireless continues to deliver resilient performance amid a stable operating environment for listed companies. With more than 90 % of Shanghai‑listed firms reporting earnings, Quectel’s core business remains solid, supported by steady cash‑flow generation and an improving profit quality that aligns with industry trends.
Implications for Tianjin Pharmaceutical Da
While the 2.6 % decline may appear modest, it signals heightened sensitivity to sector‑wide swings and investor caution amid regulatory changes affecting the pharmaceutical industry. The company’s valuation—trading below its 200‑day moving average—offers a potential entry point for long‑term investors who recognise the firm’s diversified operations and strategic partnerships.
The upcoming quarterly earnings report will likely be a key catalyst. Investors should monitor how Tianjin Pharmaceutical Da navigates the current regulatory landscape, the performance of its traditional medicine and biological product lines, and the impact of its logistics and hospital operations on overall profitability.
In sum, Tianjin Pharmaceutical Da’s recent performance sits within a broader narrative of cautious optimism in China’s pharmaceutical and technology sectors. The firm’s established market presence and strategic alliances remain its strongest assets, while regulatory developments and competitive dynamics will continue to shape its trajectory in the coming months.
